Chronic Myeloid Leukemia
Conditions
Interventions
None listed
Sponsors
The Japanese Society of Hematology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)CML-CP patients with none of the following signs of accelerated or blast phase CML: - Blasts more than 15% of peripheral blood white cells or bone marrow cells - Combined blast/promyelocyte count more than 30% in peripheral blood or bone marrow - Peripheral blood basophiles more than 20% - Extramedullary lesions other than hepato-splenomegaly 2)Patients who have given written informed consent to the study; informed consent must also be obtained from the legal representative of every patient under 20 years of age. 3)Patients who will be able to make visits to a study site as scheduled.
Exclusion criteria
Exclusion criteria: 1)Patients previously treated with any investigational drug for CML. 2)Women with confirmed or potential pregnancy, nursing mothers, and male or female patients who wish to have a child during the study period. 3)Patients with a history of allergy to imatinib, nilotinib or dasatinib. 4)Patients with any concomitant illness that contraindicates use of imatinib, nilotinib or dasatinib. 5)Patients with any other condition that, in the investigator's opinion, disqualifies them for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS) rate at 3 years after the start of 2nd-line or subsequent treatment. | — |
Countries
Japan
Contacts
Public ContactItaru Matsumura
Kinki University School of Medicine Division of Hematology, Department of Internal Medicine
Outcome results
None listed